Merih Reis Aras

Merih Reis Aras

Auto-generated profile, based on publicly available information

Merih Reis Aras

Ankara Etlik Şehir Hastanesi

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in memo - Magazine of European Medical Oncology
Verified
Journal Article
Closed access
PDF file
PTPinar Tiglioglu
Pinar Tiglioglu
MAMurat Albayrak
Murat Albayrak
MTMesut Tiglioglu
Mesut Tiglioglu
HÖHacer Berna Afacan Öztürk
Hacer Berna Afacan Öztürk
MAMerih Reis Aras
Merih Reis Aras
SMSenem Maral
Senem Maral

13 April 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
HOHacer Berna Afacan Ozturk
Hacer Berna Afacan Ozturk
MAMurat Albayrak
Murat Albayrak
SMSenem Maral
Senem Maral
MAMerih Reis Aras
Merih Reis Aras
FYFatma Yılmaz
Fatma Yılmaz
UMUmit Yavuz Malkan
Umit Yavuz Malkan
Introduction: All-trans retinoic acid (ATRA) is a physiological metabolite of vitamin A and it is used for the treatment of acute promyelocytic leukemia (APL). Hypercalcemia is a rare side effect of ATRA and it may be potentiated after interaction of ATRA with azole group antifungals. Herein, we have reported an APL case with hypercalcemia that is caused by the interaction of ATRA and posaconazole. Case Report: A 49-year-old female patient was diagnosed as APL after the examinations performed upon the detection of pancytopenia when she had presented with the complaints of widespread bruising and fever. After the initiation of posaconazole and ATRA, her serum calcium levels begin to increase (10.3 to 11.1mg/dl). Her vitamin D level was 21.9 ng/ml and PTH 17.8 pg/ml, both were in the normal ranges. The Drug Interaction Probability Scale score of our case was calculated as 6, indicating that the probable adverse drug reaction. Therefore, the high level of serum calcium was attributed to the interaction between ATRA and posaconazole. Management & Outcome: Although hypercalcemia with ATRA and other antifungal agents have been previously reported in the literature, this is the first report of hypercalcemia with the concomitant use of ATRA and posaconazole. Discussion: This case highlights the importance of monitoring ATRA’s side effects when it is used in combination with drugs inhibiting the cytochrome P450 enzymes. In conclusion, the concomitant use of posaconazole and ATRA may lead to hypercalcemia and serum calcium levels return to normal ranges with the discontinuation of these drugs.

13 November 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
FYFatma Yılmaz
Fatma Yılmaz
MAMurat Albayrak
Murat Albayrak
PTPınar Tığlıoğlu
Pınar Tığlıoğlu
MTMesut Tiglioglu
Mesut Tiglioglu
BSBuğra Sağlam
Buğra Sağlam
HÖHacer Berna Afacan Öztürk
Hacer Berna Afacan Öztürk
Introduction: Imatinib is generally well tolerated by patients. The most common ophthalmic side effects are eyelid edema and periorbital edema. Other side effects which occur at rates of <1% include blepharitis, blurred vision, conjunctival hemorrhage, conjunctivitis, retinal hemorrhage, etc. An uncommon case is here reported of a 51-year-old male with chronic myeloid leukemia who developed vitreous hemorrhage due to imatinib after 9 months of treatment. Case report: A 51-year-old male with leukocytosis detected in the blood test examination was referred to the Hematology Department. The bone marrow biopsy result was compatible with chronic myeloid leukemia. Imatinib treatment (400 mg/day) was started. In the ninth month of imatinib treatment, the patient complained of a sudden decrease in vision. Vitreous hemorrhage was detected in the left eye and the patient underwent surgery. Vitreous hemorrhage recurred 1 month after the operation. On the fourth day after the discontinuation of imatinib treatment, the patient's ophthalmic complaints improved significantly. The Naranjo algorithm was applied and a score of 9 was detected. The vitreous hemorrhage of the patient was attributed to imatinib, and so the treatment of the patient was switched to bosutinib. Discussion: Imatinib is an oral signal inhibitor that targets tyrosine kinase for BCR/ABL, platelet-derived growth factor, stem cell factor, and c-kit (CD117). The conjunctiva and sclera have a large amount of c-kit positive mast cells which are inhibited by imatinib. The inhibition of c-kit positive mast cells by imatinib may be responsible for further exposure of the conjunctival mucosa to injuries.

22 August 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
MTMesut Tiglioglu
Mesut Tiglioglu
PTPinar Tiglioglu
Pinar Tiglioglu
AYAbdulkerim Yıldız
Abdulkerim Yıldız
MAMerih Reis Aras
Merih Reis Aras
BSBuğra Sağlam
Buğra Sağlam
MAMurat Albayrak
Murat Albayrak
What is known and objective Primary myelofibrosis (PMF) is characterized by myeloid cell proliferation and prominent bone marrow fibrosis. Ruxolitinib, a selective inhibitor of JAK 1 and 2, significantly reduces constitutional symptoms and spleen size compared with placebo, and has significant clinical benefits in patients with myelofibrosis. The most common haematological side effects are thrombocytopenia and anaemia, and the most common non-haematological side effects are grade 1–2 diarrhoea and pyrexia. Leukocytoclastic vasculitis is small vessel vasculitis, characterized histopathologically by immune complex-mediated vasculitis of the dermal capillaries and venules in the lower extremities, which can be seen as palpable purpura. Although the cause is 50% idiopathic, the aetiology of leukocytoclastic vasculitis can be collected under many headings. Case Summary The case is here presented of a patient with PMF who developed leukocytoclastic vasculitis after ruxolitinib treatment. Ruxolitinib was discontinued as the lesions were thought to be drug-related and all skin lesions disappeared approximately 2 months after termination of the drug. When the ruxolitinib treatment was restarted at the same dose (2 × 15 mg), the skin lesions recurred. The drug dose was reduced to 1 × 15 mg, and the rashes disappeared. Currently, the patient has no active complaints and is being followed up with ruxolitinib 1 × 15 mg without any complications. What is new and Conclusion To the best of our knowledge, leukocytoclastic vasculitis due to ruxolitinib is extremely uncommon. This case report can be considered to contribute to the literature of this rare event.

31 May 2023 in Istanbul Medical Journal
Verified
Journal Article
Closed access
ISİsTemi Serin
İsTemi Serin
MDMehmet Hilmi Doğu
Mehmet Hilmi Doğu
OEOmer Ekinci
Omer Ekinci
GCGulsum Akgun Cagliyan
Gulsum Akgun Cagliyan
ABAbdulkadir Baştürk
Abdulkadir Baştürk
FAFevzi Altuntaş
Fevzi Altuntaş

2 March 2023 in Leukemia Research
Verified
Journal Article
Closed access
EGEbru Kilic Gunes
Ebru Kilic Gunes
ZOZubeyde Nur Ozkurt
Zubeyde Nur Ozkurt
ŞYŞeyma Yıldız
Şeyma Yıldız
GOgulsum ozet
gulsum ozet
FCFunda Ceran
Funda Ceran
MAMELTEM Ayli
MELTEM Ayli